CSIMarket
 
Protagonist Therapeutics inc   (PTGX)
Other Ticker:  
 
 
Price: $28.4600 $-0.52 -1.794%
Day's High: $29.22 Week Perf: -4.72 %
Day's Low: $ 28.25 30 Day Perf: 0.81 %
Volume (M): 906 52 Wk High: $ 33.34
Volume (M$): $ 25,793 52 Wk Avg: $22.02
Open: $28.81 52 Wk Low: $13.72



 Market Capitalization (Millions $) 1,617
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) 60
 Net Income (TTM) (Millions $) -79
 Cash Flow (TTM) (Millions $) 61
 Capital Exp. (TTM) (Millions $) 1

Protagonist Therapeutics Inc
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development of peptide-based drugs. The company's primary goal is to discover and develop innovative treatments for gastrointestinal diseases and disorders.

Protagonist Therapeutics utilizes its proprietary technology platform called Protagonist Integrative Peptide Therapeutics (IPT) to identify and optimize peptides that can target specific disease pathways. The IPT platform combines computational modeling, synthetic chemistry, and biology to design and develop these peptide-based drugs.

The company's pipeline includes various drug candidates at different stages of development, targeting different indications such as inflammatory bowel disease, gastrointestinal cancers, and polycystic kidney disease. Protagonist Therapeutics aims to address unmet medical needs and provide novel treatment options for patients in these therapeutic areas.

With a focus on advancing its drug candidates through clinical trials and securing regulatory approvals, Protagonist Therapeutics aims to become a leading company in the field of peptide-based therapeutics. The company collaborates with pharmaceutical companies and research institutions to accelerate the development of its drug candidates and expand its pipeline.


   Company Address: 7707 Gateway Boulevard, Suite 140 Newark 94560 CA
   Company Phone Number: 474-0170   Stock Exchange / Ticker: NASDAQ PTGX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Protagonist Therapeutics Inc

Serious headline: Protagonist Therapeutics Inc. Reports Impressive Revenue of $60 Million in Q4 2023

Protagonist Therapeutics Inc. (PTGX) has showcased strong performance in recent trading days, with a solid gain of 8.45%. This surge in stock price has brought the share value to 26.09% during the first quarter of 2024. PTGX stock is currently on an upward trajectory and is only 1.9% away from its 52-week high of $30.1.
One of the main contributing factors to PTGX's success is its impressive financial results. As revealed by the company, in the fiscal time-frame of October to December 31, 2023, Protagonist Therapeutics Inc. achieved a remarkable revenue of $60 million. This represents a significant improvement compared to the same quarter the previous year when the company experienced a net loss of -$34.194 million.

Protagonist Therapeutics Inc

Protagonist Therapeutics Inc. Reports Significant Operating Deficit of $-38.326 Million in Q3 2023



The Major Pharmaceutical Preparations sector has been dominated by industry leaders, while some lesser-known companies have remained somewhat overlooked. Among them is Protagonist Therapeutics Inc (PTGX), an evolving entity that recently disclosed its third-quarter financial results for 2023. Despite trailing behind the sector leaders, these results offer valuable insights into the company's current performance and its potential impact on the company's future trajectory.
Operating Deficit Trends:
In the third quarter of 2023, PTGX reported an operating deficit of $-38.326 million. To put this figure into context, it's important to analyze the company's performance in the same period of the previous year. During Q3 2022, PTGX recorded an operating deficit of $-32.303 million. This data suggests that the company's financial situation worsened, as the operating deficit increased by approximately $6 million.

Protagonist Therapeutics Inc

Protagonist Therapeutics Reports Loss of $-0.68 Per Share in Q2 2023, But Shows Signs of Recovery

Protagonist Therapeutics Inc (PTGX) has recently released its financial results for the April to June 30, 2023 fiscal span, and while the numbers may not be impressive at first glance, there are underlying factors that suggest a potential turnaround for the company. Despite a loss per share of $-0.68, an improvement from $-0.84 compared to the previous year, and an increased shortfall from the prior financial reporting period, there are reasons to remain bullish about PTGX.
One notable aspect of the financial report is the consistent revenue of $0.00 million, which remained unchanged from the previous year. While this may seem discouraging, it is essential to note that there has been no significant drop, especially considering the challenging economic conditions of the past year. In fact, the consecutive revenue stability could indicate that PTGX has reached a bottom and is poised for growth in the coming quarters.

Protagonist Therapeutics Inc

Protagonist Therapeutics Inc Reports Larger Loss in Fiscal Year Ending March 2023

Protagonist Therapeutics Inc is a biopharmaceutical company that specializes in developing peptide-based drugs to treat various diseases. The company's objective is to leverage its proprietary technology platform to create novel and targeted therapeutics that can improve outcomes for patients suffering from a wide range of medical conditions, including gastrointestinal-related issues, autoimmune disorders, and certain types of cancer.
Unfortunately, the company's financial performance for the fiscal year ending March 31, 2023, did not meet expectations. The company's diminishing returns grew to $-0.67 per share, compared to $-0.43 per share the previous year. However, the EPS improved from $-0.69 per share from the previous reporting period. Furthermore, the revenue remained unchanged at $0.00 million from $25.72 million in the corresponding reporting period a year before, and sequentially from $0.00 million.






 
  Company Estimates
  Revenue Outlook
Protagonist Therapeutics inc does not provide revenue guidance.

Earnings Outlook
Protagonist Therapeutics inc does not provide earnings estimates.

Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com